p-medicine

p-medicine

Medicine is undergoing a revolution that is transforming the nature of healthcare from reactive to preventive. The changes are catalyzed by a new systems approach to disease which focuses on integrated diagnosis, treatment and prevention of disease in individuals. This will replace our current mode of medicine over the coming years with a personalized predictive treatment. While the goal is clear, the path is fraught with challenges. P-medicine brings together international leaders in their fields to create an infrastructure that will facilitate this translation from current practice to personalized medicine. In achieving this objective p-medicine has formulated a coherent, integrated work plan for the design, development, integration and validation of technologically challenging areas of today. Our emphasis is on formulating an open, modular framework of tools and services, so that p-medicine can be adopted gradually, including efficient secure sharing and handling of large personalized data sets, enabling demanding Virtual Physiological Human (VPH) multi-scale simulations (in silico oncology), building standards-compliant tools and models for VPH research, drawing on the VPH Toolkit and providing tools for large-scale, privacy-preserving data and literature mining, a key component of VPH research. We will ensure that privacy, non-discrimination, and access policies are aligned to maximize protection of and benefit to patients. The p-medicine tools and technologies will be validated within the concrete setting of advanced clinical research. Pilot cancer trials have been selected based on clear research objectives, emphasising the need to integrate multilevel datasets, in the domains of Wilms tumour, breast cancer and leukaemia. To sustain a self-supporting infrastructure realistic use cases will be built that will demonstrate tangible results for clinicians. The project is clinically driven and promotes the principle of open source and open standards.

For further information, please visit:
http://www.p-medicine.eu

Project co-ordinator:
Universität des Saarlandes

Partners:

  • CUSTODIX NV
  • THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
  • SWISS INSTITUTE OF BIOINFORMATICS
  • ECANCERMEDICALSCIENCE AG
  • NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
  • INSTITUTE OF COMMUNICATION AND COMPUTER SYSTEMS
  • A. PERSIDIS & SIA OE
  • GOTTFRIED WILHELM LEIBNIZ UNIVERSITAET HANNOVER
  • HEINRICH-HEINE-UNIVERSITAET DUESSELDORF
  • UNIVERSIDAD POLITECNICA DE MADRID
  • IBM ISRAEL - SCIENCE AND TECHNOLOGY LTD
  • FOUNDATION FOR RESEARCH AND TECHNOLOGY HELLAS
  • FRAUNHOFER-GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V
  • PHILIPS ELECTRONICS NEDERLAND B.V.
  • UNIVERSITY COLLEGE LONDON
  • EUROPEAN RESEARCH AND PROJECT OFFICE GMBH
  • CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL
  • INSTYTUT CHEMII BIOORGANICZNEJ PAN
  • ISTITUTO EUROPEO DI ONCOLOGIA SRL

Timetable: from 01/2011 to 01/2015

Total cost: € 18.480.000

EC funding: € 13.330.000

Programme Acronym: FP7-ICT

Subprogramme Area: ICT-2009.5.3 Virtual Physiological Human

Contract type: Collaborative project (generic)

Related news articles:

Most Popular Now

Open Call HORIZON-MISS-2022-CANCER-01-04…

The overall goal of the Mission on Cancer[1] and the Europe's Beating Cancer Plan[2] includes a better quality of life for patients and their families living with, and after, cancer. Project...

Insilico Medicine Raises $60 Million in …

Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that it has completed a $60 million Series D financing from a syndicate of global investors with...

Researchers Use AI to Predict Cancer Ris…

An artificial intelligence (AI) tool helps doctors predict the cancer risk in lung nodules seen on CT, according to a new study published in the journal Radiology. Pulmonary nodules appear as...

KTU Researchers Investigate the Links Be…

In recent years Alzheimer's disease has been on the rise throughout the world and is rarely diagnosed at an early stage when it can still be effectively controlled. Using artificial...

Speech Analysis App Predicts Worsening H…

A voice analysis app used by heart failure patients at home recognises fluid in the lungs three weeks before an unplanned hospitalisation or escalation in outpatient drug treatment. The late...

Screening for Diabetic Retinopathy Prove…

Both telemedicine and community screening for diabetic retinopathy (DR) in rural and urban settings are cost-effective in China, and telemedicine screening programs are more cost-effective, according to a study led...

Philips' Future Health Index 2022 Report…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the publication of its Future Health Index (FHI) 2022 report: 'Healthcare hits reset: Priorities shift as...

Researchers Develop Smartphone-Powered M…

A University of Minnesota Twin Cities research team has developed a new microfluidic chip for diagnosing diseases that uses a minimal number of components and can be powered wirelessly by...

App Detecting Jaundice in Babies a Succe…

A smartphone app that identifies severe jaundice in newborn babies by scanning their eyes could be a life-saver in areas that lack access to expensive screening devices, suggests a study...

Head Marketing & Communications

...

InterSystems Wins Data Driven Product of…

InterSystems, a provider of next-generation solutions for enterprise digital transformation to help customers solve the most critical data challenges, has announced it received the prestigious Data Driven Product of the...

Siemens Healthineers Introduces Symbia P…

Siemens Healthineers introduces Symbia Pro.specta™, a single-photon emission computed tomography/computed tomography (SPECT/CT) system with CE Mark and Food and Drug Administration (FDA) clearance that has advanced SPECT and CT imaging...

Latest Business News

Latest Research News

Latest Conferences News

Latest Jobs